Botulinum toxin: From menace to medicine

Clinical uses of Botulinum Toxins

Volumn , Issue , 2007, Pages 27-44

  Hambleton, Peter ^a   Pickett, Andrew M ^b   Shone, Clifford C ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68849111496     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544842.003     Document Type: Chapter

References (62)

1. Scott, A. B., Rosenbaum, A. L. and Collins, C. C. (1973). Pharmaceutical weakening of extraocular muscles. Invest. Ophthalmol., 12, 924-7.
2. Scott, A. B. (1979). Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmol., 87, 1044-9.
3. Marsden, C. D. and Quinn, N. P. (1990). The dystonias. Neurological disorders affecting 20,000 people in Britain. Brit. Med. J., 300, 139-44.
4. Jankovic, J. and Brin, M. F. (1991). Therapeutic uses of botulinum toxin. New Engl. J. Med., 324, 1186-94.
5. Jankovic, J. and Hallett, M. (eds.) (1994). Therapy with Botulinum Toxin. New York: Marcel Dekker Inc.
6. Eleopra, R., Tugnoli, V., Rossetto, O., Montecucco, C. and De Grandis, D. (1997). Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in humans. Neurosci. Lett., 224, 91.
7. Eleopra, R., Tugnoli, V., Quatrale, R., Gastaldo, E., Rossetto, O., De Grandis, D. and Motecucco, C. (2002). Clin. Neurophysiol., 113, 1258-64.
8. Eleopra, R., Tugnoli, V., Rossetto, O., De Grandis, D. and Motecucco, C. (1998). Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neuroscience Lett., 256, 135-8.
9. Chen, R., Karp, B. I. and Hallett, M. (1998). Botulinum toxin type F for treatment of dystonia: long term experience. Neurology, 51, 1494-6.
10. Tugnoli, V., Marchese Ragona, R., Eleopra, R., De Grandis, D. and Montecucco, C. (2001). Treatment of Frey Syndrome with botulinum toxin type F. Arch. Otolaryngol. Head Neck Surg., 127, 339-40.
11. Sheean, G. L. and Lees, A. J. (1995). Botulinum toxin F in the treatment of torticillis clinically resistant to botulinum toxin A. J. Neurol. Neurosurg. Psychiatry, 59, 601-7.
12. Greene, P. E. and Fahn, S. (1996). Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Movement Disorders, 14, 181-4.
13. Melling, J., Hambleton, P. and Shone, C. C. (1988). Clostridium botulinum toxins: nature and preparation for clinical use. Eye, 2, 16-23.
14. Botulinum toxin type for injection. European Pharmacopoeia 5.8 (2007), 01/2005: 2113.
15. Bigalke, H. and Frevert, J. (1999). PCT patent application (PCT/DE00/0177) Therapeutic agent comprising a botulinum neurotoxin.
16. Bigalke, H. and Frevert, J. (1998). German patent application (DE19856897) Therapy for the control of snoring noises.
17. Requirements for Botulinum Toxin A for Therapeutic Use (2000). Pharmacopoeia of the Peoples Republic of China, 314-18.
18. McLellan, K., Gaines Das, R. E., Ekong, T. A. N. and Sesardic, D. (1996). Therapeutic botulinum type A toxin: factors affecting potency. Toxicon, 34, 975-85.
19. Hambleton, P. and Pickett, A. M. (1994). Dose equivalence of botulinum toxin preparations (Letter). J. R. Soc. Med., 87, 719.
20. Pearce, L. B., Borodic, G. E., First, E. R. and McCallum, B. D. (1994). Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxic Appl. Pharmacol., 128, 69-79.
21. Sesardic, D., McLellan, K., Ekong, T. A. N. and Gaines Das, R. E. (1996). Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmac. Toxic., 78, 283-8.
22. Sawtell, J. A. and Ream, A. J. (1995). Observations on the effect of the diluent used for diluting challenge toxin the clostridium botulinum potency assay. Biologicals, 23, 249-51.
23. Schantz, E. J. and Kautter, D. A. (1978). Microbiological methods: standardization assay for Clostridium botulinum toxins. J. Ass. Analyt. Chem., 61, 96-9.
24. Brin, M. F. and Blitzer, A. (1993). Botulinum toxin: dangerous terminology errors (Letter). J. R. Soc. Med., 86, 493-4.
25. Sesardic, D. (2002). Alternatives in testing of bacterial toxins and antitoxins. In F. Brown, C. Hendrikson, D. Sesardic and K. Cussler, eds., Advancing science and elimination of the use of laboratory animals for development and control of vaccines and hormones. Dev. Biol. Stand., 111, 101-8.
26. Peng, K., Merlino, G., Addeo, J., Foster, S., Spanoyannis, A. and Aoki, K. R. (1998). Botox-is six-fold more potent than Dysport-in the Mouse Digit Abduction Scoring Assay Movement Disorder Society 50th International Congress of Parkinson’s Disease and Movement Disorders P2.102.
27. Sesardic, D., Gaines Das, R. E. and Corbel, M. J. C. (1997). Botulinum toxin. J. R. Soc. Med., 87, 307.
28. Shone, C. C., Appleton, N., Wilton-Smith, P., Hambleton, P., Modi, N., Gatley, S. and Melling, J. (1986). In vitro assays for botulinum toxins and antitoxins. In I. Davidson and W. Hennessen, eds., Reduction of animal usage in the development and control of biological products. Dev. Biol. Stand. Basel: Karger, 64, 141-5.
29. Ekong, T. A. N., McLellan, K. and Sesardic, D. (1995). Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. J. Immun. Methods, 180, 181-91.
30. Sesardic, D. (2002). Alternatives in testing of bacterial toxins and antitoxins. In F. Brown, C. Hendrikson, D. Sesardic and K. Cussler, eds., Advancing science and elimination of the use of laboratory animals for development and control of vaccines and hormones. Basel: Karger, 111, 101-8.
31. Hallis, B., James, B. A. F. and Shone, C. C. (1996). Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol., 34, 1934-8.
32. Schantz, E. J. and Johnson, E. A. (1992). Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiological Reviews, 56(1), 80-99.
33. The Management, Design and Operation of Microbiological Containment Laboratories HSE Books, 2001, ISBN 0717620344.
34. Li Zhang, Wei-Jen Lin, Shengwen Li and Roger Aoki, K. (2003). Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene, 315, 21-32.
35. Bradshaw, M., Dineen, S. S. and Johnson, E. A. (2001). Regulation of Botulinum Neurotoxin Expression reviewed in Annual Report of the University of Wisconsin Food Research Institute, 2001, 13-15.
36. Hunt, T. J. (2000). PCT patent application (PCT/US01/03641) Botulinum Toxin Pharmaceutical Compositions.
37. Gill, D. M. (1982). Bacterial toxins: a table of lethal amounts. Microbiological Reviews, 46(1), 86-94.
38. Prescribing information for BOTOX-(Botulinum Toxin Type A) Purified Neurotoxin Complex, July 2002.
39. Food and Drug Administration Medical Officer’s review of BOTOX-submission for treatment of glabellar facial lines, November 9, 2001 and March 4, 2002, page 10 (as published by FDA).
40. Aoki, K. R. (1999). Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum toxin preparations. European Journal of Neurology, 6(Suppl. 4), S3-S10.
41. Aoki, K. R. and Wheeler, L. (2000). A comparison of the efficacy and safety of Botox-and Dysport-in mice. Movement Disorders, 15(Suppl. 3), 35.
42. Aoki, K. R. and Guyer, B. (2001). Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. European Journal of Neurology, 8(Suppl. 5), 21-9.
43. Inoue, K., Fujinaga, Y., Watanabe, T., Ohyama, T., Takeshi, K., Moriishi, K., Nakajima, H., Inoue, K. and Oguma, K. (1996). Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun., 64, 1589-94.
44. Ohishi, I., Sugii, S. and Sakaguchi, G. (1977). Oral toxicities of Clostridium botulinum in reponse to molecular size. Infect. Immun., 16, 107-9.
45. Dodd, S. L., Rowell, B. A., Vrabas, I. S., Arrowsmith, R. J. and Weatherill, P. J. (1998). A comparison of the spread of three formulations of neurotoxin A as determined by effects on muscle function. Eur. J. Neurol., 5, 181-6.
46. Schiavo, G., Matteoli, M. and Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. Physiol. Rev., 80, 717-66.
47. Boyd, R. S., Duggan, M. J., Shone, C. C. and Foster, K. A. (1995). The effect of botulinum neurotoxins on the release of insulin from insulinoma cell lines HIT-15 and RINm5F. J. Biol. Chem. (Commun.), 270, 18216-18.
48. Gaisano, H. Y., Sheu, L., Foskett, J. K. and Trimble, W. S. (1994). Tetanus toxin light chain cleaves a vesicle-associated membrane protein (VAMP) isoform-2 in rat pancreatic zymogen granules and inhibits secretion. J. Biol. Chem., 269, 17062-6.
49. Chen, F., Foran, P., Shone, C. C., Foster, K., Melling, J. and Dolly, O. (1997). Botulinum type B inhibits insulin-stimulated glucose uptake into adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Biochemistry, 36, 5719-28.
50. Chaddock, J. A., Purkiss, J. R., Duggan, M. J., Quinn, C. P., Shone, C. C. and Foster, K. A. (2000a). A conjugate composed of nerve growth factor and a non-toxic derivative of botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors, 18, 147-55.
51. Chaddock, K., Purkiss, J., Friss, L., Broadbridge, J., Duggan, M., Shone, C., Quinn, C. and Foster, K. (2000b). Inhibition of neurotoxin release by a retargeted endopeptidase derivative of C. botulinum type A. Infect. Immun., 68, 2587-93.
52. Welch, M. J., Purkiss, J. R. and Foster, K. A. (2000). Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 38, 245-58.
53. Duggan, M. J., Quinn, C. P., Chaddock, J., Purkiss, J. R., Alexander, F., Doward, S., Fooks, S. J., Friis, L., Hall, Y., Kirby, E., Leeds, N., Moulsdale, H. J., Dickenson, A., Green, M., Rahman, W., Suzuki, R., Shone, C. C. and Foster, K. A. (2002). Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem., 277, 34846-52.
54. Bigalke, H. and Frevant, J. (2003). US patent application (US2003059912): Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof.
55. Francis, J. W., Brown, R. H., Figueiredo, D., Remington, M. P., Castillo, O., Schwarzschild, M. A., Fishman, P. S., Murphy, J. R. and vanderSpec, J. C. (2000). Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potent vector for delivering heterologous proteins to neurons. J. Neurochem., 74, 2528-36.
56. Schneider, H., Groves, M., Muhle, C., Reynolds, P. N., Knight, A., Themis, M., Carvajal, J., Scaravilli, F., Curiel, D. T., Fairweather, N. F. and Coutelle, C. (2000). Retargeting of adenoviral vectors to neurons using the Hc fragment of tetanus toxin. Gene Ther., 18, 1584-92.
57. Knight, A., Carvajal, J., Schneider, H., Coutelle, C., Chamberlain, S. and Fairweather, N. (1999). Non-viral neuronal gene delivery mediated by the Hc fragment of tetanus toxin. Eur. J. Biochem., 259, 762-9.
58. Goodnough, M. C., Oyler, G., Fishman, P. S., Johnson, E. A., Neale, E. A., Keller, J. E., Tepp, W. H., Clark, M., Hartz, S. and Adler, M (2002). Development of a neuronal delivery vector for the intracellular transport of botulinum neurotoxin agonists. FEBS Lett., 513, 163-8.
59. Li, Y., Foran, P., Lawrence, G., Mohammed, N., Chan-Kwo-Chion, C. K., Lis, G., Aoki, R. and Dolly, J. O. (2001). Recombinant forms of tetanus toxin engineered for examining and exploiting neuronal trafficking pathways. J. Biol. Chem., 276, 31394-401.
60. Dolly, J. O., Wheeler, L. A., Aoki, R. K. and Garst, M. A. (2001). US Patent application (US62003794): Modification of clostridial toxins for use as transporter proteins.
61. Simpson, L. L., Maksymowych, A. B. and Kiyatkin, N. (1999). Botulinum toxin as a carrier for oral vaccines. Cell. Mol. Life Sci., 56, 47-61.
62. Park, J. B. and Simpson, L. L. (2003). Inhalation poisoning by botulinum toxin and inhalation vaccine with its heavy chain component. Infect. Immun., 71, 1147-54.